Soligenix Inc Stock Price, News & Analysis

Soligenix, Inc. (SNGX) has announced a strategic partnership with SERB Pharmaceuticals to exclusively license its ricin antigen for the development of a therapeutic treatment against ricin poisoning. This partnership aims to address a significant unmet medical need, as there are currently no therapeutic options available for ricin toxin exposure. Furthermore, Soligenix is advancing its own ricin vaccine, RiVax®, supported by over $30 million in government funding. The specific terms of the licensing agreement remain undisclosed.

Soligenix, Inc. (NASDAQ: SNGX) announced the publication of positive results from its Phase 3 FLASH study of HyBryte^™ in the treatment of cutaneous T-cell lymphoma (CTCL) in JAMA Dermatology. The study demonstrated a statistically significant reduction in lesion size, with 49% of patients achieving a response after 18 weeks of treatment. HyBryte^™ showed strong efficacy and safety, addressing the critical need for effective treatments in CTCL. The results highlight the potential of HyBryte^™ to set a new standard in CTCL therapy, indicating promising next steps for regulatory approval.

Soligenix, Inc. (Nasdaq: SNGX) announced FDA clearance of its IND application for a Phase 2a clinical trial of SGX302, targeting mild-to-moderate psoriasis. The trial aims to assess the safety and efficacy of topically-applied synthetic hypericin, with patient enrollment expected in Q4 2022. Previously, synthetic hypericin showed promising results in a Phase 1/2 trial for psoriasis. The global psoriasis market is projected to grow from $15 billion in 2020 to $40 billion by 2027, highlighting the potential impact of successful results from this trial.

Soligenix, Inc. (SNGX) announced a significant milestone: their bivalent vaccine demonstrated 100% protection in non-human primates against lethal Marburg and Sudan viruses. This subunit vaccine, developed in collaboration with the University of Hawaiʻi, features a thermostabilized formulation that can be stored at higher temperatures, enhancing public health response capabilities. The vaccine platform also shows promise for future health emergencies, including potential pandemic scenarios. Supported by NIH funding, the program continues to advance toward commercialization.

Soligenix, Inc. (Nasdaq: SNGX) announced a publication in the Journal Structure detailing the binding of its Innate Defense Regulator (IDR), dusquetide, to the p62 protein. Dusquetide shows anti-infective, anti-tumor, and anti-inflammatory properties, having reduced severe oral mucositis (SOM) rates in clinical trials. The Phase 3 study demonstrated significant results for its primary endpoint, supporting dusquetide's potential for HNC treatment. With a strong intellectual property position and ongoing research, Soligenix is exploring product opportunities for dusquetide and its analogs.

Soligenix, Inc. (Nasdaq: SNGX) announced a Notice of Allowance from the USPTO for its patent application on thermally stable trivalent filovirus vaccines. The vaccine platform combines glycoprotein antigens with nanoemulsion adjuvants, demonstrating efficacy against Ebola and Marburg viruses. It shows stable performance at high temperatures, enhancing storage logistics for vaccine distribution in outbreak scenarios. The vaccine candidate has exhibited protection in non-human primates, and the project is supported by NIH grants.

Soligenix, a late-stage biopharmaceutical company focusing on rare diseases, will present at the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022. Their on-demand presentation is scheduled for May 24 at 7 AM ET. Attendees can schedule one-on-one meetings with Soligenix management during the event. The company is advancing the commercialization of HyBryte™ (SGX301) for cutaneous T-cell lymphoma and developing other therapeutics for various conditions. For more information, visit their website or the conference site.

Soligenix, Inc. (Nasdaq: SNGX) reported its financial results for Q1 2022, with revenues of $0.2 million, up from $0.1 million in Q1 2021. The company incurred a net loss of $4.3 million, increasing from $2.4 million in the previous year. Key upcoming milestones include submitting a New Drug Application for HyBryte™ for cutaneous T-cell lymphoma and initiating a Phase 2a trial for SGX302 in psoriasis. With $22.9 million in cash and government funding support, Soligenix is positioned to advance its product development strategies.

Soligenix, Inc. (Nasdaq: SNGX) announced it has secured approximately $1.4 million in non-dilutive funding through government tax programs. This includes $1.2 million from New Jersey's Technology Business Tax Certificate Transfer Program and $0.2 million from the UK's HMRC R&D Tax Credit Program. Over the past twelve years, Soligenix has received about $7.6 million in non-dilutive funding, supporting its rare disease pipeline. They plan to file a new drug application for HyBryte™, treating cutaneous T-cell lymphoma, later this year.